0.3061
前日終値:
$0.3399
開ける:
$0.32
24時間の取引高:
2.53M
Relative Volume:
0.47
時価総額:
$38.15M
収益:
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.2041
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-17.76%
1か月 パフォーマンス:
-36.23%
6か月 パフォーマンス:
-84.85%
1年 パフォーマンス:
-93.12%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
MRSN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MRSN
Mersana Therapeutics Inc
|
0.3061 | 38.15M | 36.86M | -171.67M | -171.05M | -1.50 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-06 | 開始されました | William Blair | Outperform |
2024-11-15 | 再開されました | Citigroup | Buy |
2024-03-19 | アップグレード | JP Morgan | Underweight → Neutral |
2024-02-29 | アップグレード | BTIG Research | Neutral → Buy |
2024-02-29 | アップグレード | Guggenheim | Neutral → Buy |
2024-02-29 | アップグレード | Wedbush | Neutral → Outperform |
2023-12-04 | アップグレード | Citigroup | Neutral → Buy |
2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2023-07-27 | ダウングレード | BTIG Research | Buy → Neutral |
2023-07-27 | ダウングレード | Citigroup | Buy → Neutral |
2023-07-27 | ダウングレード | Guggenheim | Buy → Neutral |
2023-07-27 | ダウングレード | JP Morgan | Neutral → Underweight |
2023-07-27 | ダウングレード | Truist | Buy → Hold |
2023-07-27 | ダウングレード | Wedbush | Outperform → Neutral |
2023-06-16 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-06-15 | 開始されました | Guggenheim | Buy |
2023-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
2023-01-20 | 開始されました | Citigroup | Buy |
2022-11-21 | 開始されました | Truist | Buy |
2021-10-15 | 再開されました | BTIG Research | Buy |
2021-08-30 | 開始されました | H.C. Wainwright | Buy |
2021-03-31 | 開始されました | Credit Suisse | Neutral |
2020-12-03 | 開始されました | Stifel | Buy |
2020-09-29 | 再開されました | JP Morgan | Neutral |
2020-04-29 | 開始されました | BTIG Research | Buy |
2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
2019-03-11 | ダウングレード | JP Morgan | Neutral → Underweight |
2018-11-14 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2018-05-08 | 開始されました | Robert W. Baird | Outperform |
2018-03-19 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Mersana Therapeutics Inc (MRSN) 最新ニュース
When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com
Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire
FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India
MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada
MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St
Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World
Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey
Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges - TipRanks
Mersana Therapeutics Reports Progress and Financial Results - TipRanks
Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains - TipRanks
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast - Investing.com India
Mersana Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mersana Therapeutics reports Q4 EPS (11c), consensus (17c) - TipRanks
Mersana Therapeutics, Inc. SEC 10-K Report - TradingView
Mersana Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Mersana Therapeutics Announces Positive Phase 1 Clinical Data - TipRanks
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow - StockTitan
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Mersana Therapeutics faces Nasdaq delisting over share price - Investing.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa
Mersana Therapeutics Inc (MRSN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):